Effects of obesity on insulin: insulin-like growth factor 1 hybrid receptor expression and Akt phosphorylation in conduit and resistance arteries.


Journal

Diabetes & vascular disease research
ISSN: 1752-8984
Titre abrégé: Diab Vasc Dis Res
Pays: England
ID NLM: 101234011

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 9 10 2018
medline: 14 8 2019
entrez: 9 10 2018
Statut: ppublish

Résumé

Insulin and insulin-like growth factor-1 stimulate specific responses in arteries, which may be disrupted by diet-induced obesity. We examined (1) temporal effects of high-fat diet compared to low-fat diet in mice on insulin receptor, insulin-like growth factor-1 receptor, insulin receptor/insulin-like growth factor-1 receptor hybrid receptor expression and insulin/insulin-like growth factor-1-mediated Akt phosphorylation in aorta; and (2) effects of high-fat diet on insulin and insulin-like growth factor-1-mediated Akt phosphorylation and vascular tone in resistance arteries. Medium-term high-fat diet (5 weeks) decreased insulin-like growth factor-1 receptor expression and increased hybrid expression (~30%) only. After long-term (16 weeks) high-fat diet, insulin receptor expression was reduced by ~30%, insulin-like growth factor-1 receptor expression decreased a further ~40% and hybrid expression increased a further ~60%. Independent correlates of hybrid receptor expression were high-fat diet, duration of high-fat diet and plasma insulin-like growth factor-1 (all p < 0.05). In aorta, insulin was a more potent activator of Akt than insulin-like growth factor-1, whereas in resistance arteries, insulin-like growth factor-1 was more potent than insulin. High-fat diet blunted insulin-mediated vasorelaxation ( p < 0.01) but had no effect on insulin-like growth factor-1-mediated vasorelaxation in resistance arteries. Our findings support the possibility that hybrid receptor level is influenced by nutritional and metabolic cues. Moreover, vessel-dependent effects of insulin and insulin-like growth factor-1 on vascular tone and Akt activation may have implications in treating obesity-related vascular disease.

Identifiants

pubmed: 30295509
doi: 10.1177/1479164118802550
pmc: PMC6484231
doi:

Substances chimiques

Antigens, CD 0
IGF1 protein, human 0
IGF1R protein, human 0
Igf1r protein, mouse 0
Insulin 0
Receptors, Somatomedin 0
Insulin-Like Growth Factor I 67763-96-6
INSR protein, human EC 2.7.10.1
Receptor, IGF Type 1 EC 2.7.10.1
Receptor, Insulin EC 2.7.10.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

160-170

Subventions

Organisme : British Heart Foundation
ID : FS/12/80/29821
Pays : United Kingdom

Références

Endocrinology. 2009 Oct;150(10):4575-82
pubmed: 19608653
Diabetes. 2008 Dec;57(12):3307-14
pubmed: 18835939
Biochem J. 1997 Oct 1;327 ( Pt 1):209-15
pubmed: 9355755
J Biol Chem. 2006 Sep 8;281(36):25869-74
pubmed: 16831875
J Clin Endocrinol Metab. 1994 Jul;79(1):230-2
pubmed: 8027233
Diabetes. 2011 Aug;60(8):2169-78
pubmed: 21677284
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Diabetes. 1998 Jan;47(1):87-92
pubmed: 9421379
Endocrinology. 2005 Nov;146(11):4690-6
pubmed: 16099860
J Clin Endocrinol Metab. 2000 Nov;85(11):4219-23
pubmed: 11095457
PLoS One. 2013 Nov 18;8(11):e79710
pubmed: 24260289
Curr Biol. 2009 Aug 11;19(15):R657-66
pubmed: 19674551
Sci Rep. 2015 Jan 21;5:7911
pubmed: 25604425
J Clin Invest. 1996 Dec 15;98(12):2887-93
pubmed: 8981937
Diabetes. 2012 Sep;61(9):2359-68
pubmed: 22733797
J Clin Invest. 1999 Aug;104(4):447-57
pubmed: 10449437
Curr Opin Struct Biol. 2007 Dec;17(6):699-705
pubmed: 17851071
Endocr Rev. 2009 Oct;30(6):586-623
pubmed: 19752219
Cell Metab. 2011 Sep 7;14(3):390-402
pubmed: 21907144
J Hypertens. 2005 Feb;23(2):351-8
pubmed: 15662223
Biochem J. 1993 Mar 1;290 ( Pt 2):419-26
pubmed: 8452530
Diabetes. 2013 Jun;62(6):2130-4
pubmed: 23349484
Trends Endocrinol Metab. 2016 Feb;27(2):96-104
pubmed: 26712712
Hypertension. 1999 Jul;34(1):89-95
pubmed: 10406829
Diabetes. 1999 Dec;48(12):2277-85
pubmed: 10580414
Biochem J. 1998 Aug 1;333 ( Pt 3):825-31
pubmed: 9677346

Auteurs

Romana S Mughal (RS)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Katherine Bridge (K)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Irma Buza (I)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Rita Slaaby (R)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Jesper Worm (J)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Gro Klitgaard-Povlsen (G)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Henning Hvid (H)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Marianne Schiødt (M)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Richard Cubbon (R)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Nadira Yuldasheva (N)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Anna Skromna (A)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Natallia Makava (N)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Grith Skytte-Olsen (G)

2 Global Research, Novo Nordisk A/S, Malov, Denmark.

Mark T Kearney (MT)

1 Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH